您现在的位置是:l 0 b 6 a e b r t 5 d l i 2 n y x i 1 o f 8 2 h 6 > Knowledge
【jack and jill montgomery county】As Biotech Thrives On Vaccine Hopes, Traders Look Into The Sector's Diversity
l 0 b 6 a e b r t 5 d l i 2 n y x i 1 o f 8 2 h 62024-09-29 10:14:56【Knowledge】9人已围观
简介If there is one prevailing trend that Wall Street is counting on during this period of great economi jack and jill montgomery county
If there is jack and jill montgomery countyone prevailing trend that Wall Street is counting on during this period of great economic and social uncertainty, it’s the promise of biotech and pharmaceutical companies to seemingly save the world.
At the very least, they’re relying on the sector to save the market. Throughout 2020, returns from healthcare indexes such as the Russell 1000 Healthcare Index and the MSCI World Health Care Index have routinely outperformed broad market indexes like the S&P 500 and MSCI Europe and Asia Indexes. What’s more, the latest earnings results from the sector have shown
nearly 90% of companies exceeding analyst expectations
.
2020 Index Performances By Total Returns
pph_marketperf_2020.11.png
Source: Factset; Data as of November 16, 2020
Because of the growth outlook for the sector and the massive amount of interest surrounding it, trading research platform
VantagePoint
plans to focus on biotech and other exciting market sectors in an
upcoming free demonstration
of the predictive software’s A.I.-enhanced features.
In anticipation of the live demonstration, let’s take a look at some of the biggest movers in the biotech sector currently as well as some of the factors influencing their price moves.
The Pandemic Seizes The Market
Of course, Many of the major constituents driving growth in the biotech and pharmaceutical sector are tied in with the research and development of various vaccines, treatments and testing apparatuses aimed at combating the ongoing COVID-19 pandemic. And with news and trial results emerging and evolving on a near daily basis, traders are discovering new avenues by which to profit from the sector.
Don’t get caught off-guard again, learn how Predictive A.I. can improve your trades
While positive late-stage vaccine trial results from the likes of
BioNTech SE
(NASDAQ:
BNTX
) and
Novavax
(NASDAQ:
NVAX
), alongside or in partnership with pharmaceutical giants like
Pfizer Inc
. (NYSE:
PFE
) and
Moderna, Inc
. (NASDAQ:
MRNA
), have obviously boosted the valuation of these companies. Each of these stocks are sitting at or near 52-week highs heading into December.
However, in addition to following the breaking news on these stocks, traders have also gravitated toward other companies involved in developing alternative vaccines or treatment in the wake of the advance guard.
Growth Throughout The Industry
Because while the leading COVID-19 vaccine candidates have garnered a high price tag, there are an array of follow-up companies that aim to deliver vaccines and treatments with different mechanisms of action from those currently dominating the headlines.
Story continues
This includes firms like
Inovio Pharmaceuticals, Inc.
(NASDAQ:
INO
) and
AstraZeneca PLC
(NASDAQ:
AZN
), which stocks have both wavered as they have trailed Moderna and Pfizer in producing successful trial results in their respective vaccine formulations.
However, as vaccine approval and distribution ramps up and supply chain and efficacy issues begin to influence the market, additional news from Inovio and AstraZeneca may prove critical as the world attempts to find the quickest and safest path away from the pandemic.
Discover how VantagePoint’s predictive analysis could help you avoid potential losses
Another stock with potential surprise in store is
Merck & Co, Inc
. (NYSE:
MRK
). Although relatively quiet through the race for a vaccine, the company
has invested heavily in M&A
in an attempt to round out their vaccine research. Add to that the firm’s strong Q3 earnings report that well surpassed analyst expectations and even showed modest year-over-year growth and Merck stands as something of a dark horse in the biotech sector.
Anticipate The Unexpected
Ultimately, there is still a good deal of uncertainty still at play in the market thanks to the persistence of the global pandemic.
While biotech may be a prime driver of equity as the market’s hopes for a quick recovery outweigh its fear of the virus, traders should nonetheless leverage the best in institutional-level technology and analysis to anticipate market trends up to three days in advance.
To find out more,
click here to sign up
for an upcoming demonstration of VantagePoint’s cutting-edge research and analysis software.
See more from Benzinga
Click here for options trades from Benzinga
FlowerHire X Leverages Tech To Set A New Precedent In Fostering Talent In The Cannabis Industry
Are Gambling Stocks A Strong Bet In An Uncertain Market?
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
很赞哦!(43)
相关文章
- Gofore Plc: Gofore Plc - Managers' transactions - Virtanen
- Apple’s China Trouble Makes Trump’s Trade War Harder to Defend
- One Thing To Remember About The Vital Metals Limited (ASX:VML) Share Price
- Treasuries ETFs Are Making a Comeback on Safety Bets
- Guidewire (GWRE) Q3 Earnings & Revenues Top Estimates, Stock Up
- South Koreans seek Nippon Steel asset seizure in 'forced labour' case
- Oversea Unit of World’s Largest Tobacco Producer Eyes Hong Kong IPO
- BRIEF-Great Chinasoft Technology And Partners Plan Financial Technology Buyout Fund Worth 1 Bln Yuan
- S&P 500 Preview – Security Software and Retail Headline Tuesday’s Earnings
- Read This Before Buying Five Below, Inc. (NASDAQ:FIVE) Shares
热门文章
站长推荐
5%, led by a 17% increase in average ticket and a slight decline in traffic. Growth in the quarter reflected the impact of households stocking up on essentials like paper goods and cleaning supplies as the pandemic became a nationwide concern, along with strength in discretionary categories as the quarter came to a close and stimulus dollars and tax refunds were disbursed.
As shown below, the results in the quarter materially changed the trend in two-year stacked comps for each of the banners, along with a significant acceleration for consolidated comps.
The increase in consolidated comps was the primary driver of an 8% increase in revenues to $6.3 billion. The company ended the quarter with 15,370 locations, up less than 1% year-over-year. This reflects a 7% increase in Dollar Tree units, offset by a 4% decline in Family Dollar units.
The top-line results at each banner flowed through to their respective income statements, with Dollar Tree gross margins and operating margins declining year-over-year while Family Dollar gross margins and operating margins expanded year-over-year. On a consolidated basis, gross margins contracted by 120 basis points in the quarter to 28.5%, reflective of a shift to lower-margin consumables, tariff costs and the impact of markdowns from the Easter headwinds at the Dollar Tree banner. The company saw slight operating leverage on SG&A from higher comps, with the net result being an 80 basis point contraction in operating margins to 5.8%, with operating income declining 5% to $366 million. This is not adjusted for $73 million of pandemic-related costs, such as PPE supplies.
In the first quarter, the company opened 85 stores (net of closures) and completed 220 Family Dollar renovations to the H2 format. Importantly, comps at renovated Family Dollar stores continue to outpace the chain average by more than 10%. On the call, management indicated that they plan on reducing both the number of new store openings (from 550 to 500) and the number of H2 renovations (from 1,250 to 750) in 2020.
Personally, given the fact that Family Dollar is seeing material benefits to its business from the pandemic with new or lapsed customers coming into its stores, I think the company should try to get more aggressive with its renovation plans, not less. On the other hand, you could argue that renovations cause short-term disruptions and limit their ability to fully capitalize on the business momentum they are currently experiencing.
As a result of fewer new stores and remodels, management now expects 2020 capital expenditures to total $1.0 billion compared to previous guidance of $1.2 billion. In addition, the company has temporarily suspended share repurchases. At quarter's end, the company had $1.8 billion in cash on its balance sheet compared to $4.3 billion in total debt.
Conclusion
In recent years, Dollar Tree has been a tale of two cities. While its namesake banner has generally delivered impressive financial results, Family Dollar has been a persistent underperformer. This quarter, those results flipped, and given what we've seen in the weeks since quarter's end, there's a decent possibility that we will see something similar in the coming months. As the CEO noted, the second quarter is off to a very good start at Family Dollar.
Here's the important question: how useful is that information is in terms of making future predictions about the business? Will recent success at Family Dollar translate into long-term success for the banner? The optimistic take is that new or lapsed customers, especially those visiting the renovated stores, could become recurring business for the banner. The pessimistic take is that they have experienced short-term success out of necessity as people went to any store that was open to try and find essentials like toilet paper and hand sanitizer that were largely out of stock throughout the retail landscape. From that view, many of these customers could abandon the retailer when life returns to normal. As Philbin noted on the conference call, early on [during the pandemic], folks needed us. Will people still shop as much at Family Dollar when it's no longer a necessity?
Personally, I do not place too much weight on the recent results. I will need to see incremental data points that indicate that Family Dollar has truly won sustained business from these new customers. While I still believe that the Dollar Tree banner is a well-positioned retailer with attractive unit returns, I'm not yet willing to say the same thing for Family Dollar. For that reason, along with the recent run-up in the stock price, I plan on staying on the sidelines for now.
Disclosure: None
Read more here:
Under Armour: A Tough Start to 2020
Walmart: Continued Omni-Channel Progress
Match: An Impressive Start to 2020
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
This article first appeared on
GuruFocus
.
Warning! GuruFocus has detected 4 Warning Signs with DLTR. Click here to check it out.
DLTR 30-Year Financial Data
The intrinsic value of DLTR
Peter Lynch Chart of DLTR
View comments
Lufthansa warns profits to slide again this year
US STOCKS-Bank, energy stocks lift Wall Street higher in choppy session
Florida's Highway Safety Report Finds Crashes Continue to Decrease at Red-Light Safety Camera Intersections
How Avadel (AVDL) Stock Stands Out in a Strong Industry
Zacks Rank #5 Additions for Monday
Is Shubhlaxmi Jewel Art Limited’s (NSE:SHUBHLAXMI) ROE Of 15% Impressive?
Oil & Gas - Pipeline MLP Outlook: Near-Term Prospects Bleak
友情链接
- Are Investors Undervaluing American Outdoor Brands (AOBC) Right Now?
- Were Hedge Funds Right About Caterpillar (CAT)?
- ValOre Initiates Multi-faceted Optimization Testwork at Pedra Branca and Receives Preliminary Platsol™ Metallurgical Recoveries of 93.4% for Palladium and 95.3% for Platinum
- Our Take On Avery Dennison's (NYSE:AVY) CEO Salary
- Analysts Estimate Stitch Fix (SFIX) to Report a Decline in Earnings: What to Look Out for
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
- Oil Price Fundamental Daily Forecast – OPEC+ to Discuss Production Cut Extension to September 1
- High-Yield ETF Rout Widens Gap With Benchmarks
- Pennsylvania's Democratic governor calls Trump remarks 'partisan attack'
- Has TerraForm Power (TERP) Outpaced Other Utilities Stocks This Year?